Gender-based differences in hemostatic responses

• Shaw LJ , BugiardiniR, MerzNB. Women and ischemic heart disease. J. Am. Coll. Cardiol.54, 1561–1575 (2009).
   PubMed Web of Science ®Google Scholar
• Rosamund W , FlegalK, FurieKet al.; for the Writing Group Members. Heart disease and stroke statistics – 2008 update: a report from the American Heart Association Statistics Committee and stroke statistics subcommittee. Circulation117, e25–e146 (2008).
   PubMed Web of Science ®Google Scholar
• Heron MP , HoyertDL, XuJ, ScottC, Tejada-VeraB. Deaths: preliminary data for 2006. Natl Vital Stat. Rep.56, 1–52 (2008).
   Google Scholar
• Bairey Merz CN , ShawLJ, ReissSE. Ischemic heart disease in women: insights from the NHLBI-sponsored Women’s Ischemic Syndrome Evaluation (WISE) Study. J. Am. Coll. Cardiol.47(Suppl. 3), S21–S29 (2006).
   Google Scholar
• Mosca L , BankaCL, BenjaminEJet al.; for the Expert Panel/Writing Group. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. J. Am. Coll. Cardiol.49, 1230–1250 (2007).
   PubMed Web of Science ®Google Scholar
• Benjamin EJ , SmithSC Jr, CooperRS, HillMN, LuepkerRV. Task force #1 – magnitude of the prevention problem: opportunities and challenges. 33rd Bethesda Conference. J. Am. Coll. Cardiol.40, 588–603 (2002).
   PubMed Web of Science ®Google Scholar
• Roger VL , JacobsenSJ, WestonSAet al. Trends in the incidence and survival of patients with hospitalized myocardial infarction, Olmstead County, Minnesota, 1979 to 1994. Am. Intern. Med.136, 341–348 (2002).
   Web of Science ®Google Scholar
• Bugiardini R , YanAT, YanRTet al. Factors influencing underutilization of evidence-based therapies in women. Eur. Heart J.32, 1337–1344 (2011).
   PubMed Web of Science ®Google Scholar
• Johnston N , Schenck-GustafssonK, LagerqvistB. Are we using the cardiovascular medications and coronary angiography appropriately in men and women with chest pain. Eur. Heart J.32, 1331–1336 (2011).
   PubMed Web of Science ®Google Scholar
• Fricker J . Women’s heart health: the focus of this issue. Eur. Heart J.32, 1333 (2011).
   Web of Science ®Google Scholar
• Merz CV. The Yentl syndrome is alive and well. Eur. Heart J.32, 1313–1315 (2011).
   PubMed Web of Science ®Google Scholar
• Ridker PM , CookNR, LeeIMet al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med.352, 1293–1304 (2005).
   PubMed Web of Science ®Google Scholar
• Shaw LJ , Bairey MerzCN, PepineCJet al. Insights from the NHLBI-sponsoredWomen’s Ischemia Syndrome Evaluation (WISE) Study Part 1: gender differences in traditional and novel risk factors, symptom evaluation and gender optimized diagnostic strategies. J. Am. Coll. Cardiol.47, S4–S20 (2006).
   PubMed Web of Science ®Google Scholar
• Shaw LJ , BugiardiniR, MerzCN. Women and ischemic heart disease: evolving knowledge. J. Am. Coll. Cardiol.54, 1561–1575 (2009).
   PubMed Web of Science ®Google Scholar
• Walenga JM , BaraL, PetitouM, SamamaM, FareedJ, ChoayJ. The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity. Thromb. Res.51(1), 23–33 (1988).
   PubMed Web of Science ®Google Scholar
• Walenga J , HoppensteadtD, KujawskiMet al. Biochemical and pharmacological validation of the antithrombotic anticoagulant potential of foundaparinux, enoxaparin, and otamixaban as it impacts the management of ACS. Circulation116, 482–483 (2007) (Abstract 2.9).
   Web of Science ®Google Scholar
• Kujawski MRF . Molecular weight dependence on the inhibition of thrombin activatable fibrinolytic inhibitor (TAFI) by heparins. Thesis, Loyola University of Chicago, Volume II, 333–335 (2007).
   Google Scholar
• Iacoviello L , DicastelnuouvoA, DeknijffPet al. Polymorphism in the coagulation factor VII gene and the risk of myocardial infarction. N. Engl. J. Med.338, 79–85 (1998).
   PubMed Web of Science ®Google Scholar
• Ernst E , ReschKI. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann. Intern. Med.118 (12), 956–963 (1993).
   PubMed Web of Science ®Google Scholar
• Barasch E , BenderlyM, GraffEet al. Plasma fibrinogen levels and their correlates in 6457 coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) study. J. Clin. Epidemiol.48, 757–765 (1995).
   PubMed Web of Science ®Google Scholar
• Hajjar KA , GavishD, BreslowJLet al. Lipoprotein(a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature339, 303–305 (1989).
   PubMed Web of Science ®Google Scholar
• Hamsten A , de FaireU, WalldiusGet al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet2, 3–9 (1987).
   PubMed Web of Science ®Google Scholar
• Jansson JH , NilssonTK, JohnsonO. von Willebrand factor in plasma: risk factor for recurrent myocardial infarction and death. Br. Heart J.66, 351–355 (1991).
   PubMedGoogle Scholar
• Folsom AR , WuKK, RosamondWDet al. Prospective study of the hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation96, 1102–1108 (1997).
   PubMed Web of Science ®Google Scholar
• Schwertz DW , PenckoferS. Sex differences and the effects of sex hormones on hemostasis and vascular reactivity. Heart Lung30, 401–426 (2001).
   PubMed Web of Science ®Google Scholar
• Kalaria VG , ZarebaW, MossAJet al. Gender-related differences in thrombogenic factors predicting recurrent cardiac events in patients after acute myocardial infarction. Am. J. Cardiol.85, 1401–1408 (2000).
   PubMed Web of Science ®Google Scholar
• Capodanno D , AngiolilloDJ. Impact of race and gender on antithrombotic therapy. Thromb. Haemost.104, 471–484 (2010).
   PubMed Web of Science ®Google Scholar
• Blomkalns AL , ChenAY, HochmanJSet al.; CRUSADE Investigators. Gender disparities in the diagnosis and treatment of non-ST segment elevation acute coronary syndrome: large-scale observations from the CRUSADE (Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines) National Quality Improvement Initiative. J. Am. Coll. Cardiol.45, 802–836 (2005).
   Google Scholar
• Kim ESH , MononV. Status of women in cardiovascular clinical trails. Arterioscler. Thromb. Vasc. Biol.29, 279–283 (2009).
   PubMed Web of Science ®Google Scholar
• Chiaramonte GR , FriendR. Medical students’ and residents’ gender bias in diagnosis, treatment and interpretation of coronary heart disease symptoms. Health Psychol.25, 255–266 (2006).
   PubMed Web of Science ®Google Scholar
• Rossouw JE , AndersonGL, PrenticeRLet al.; Writing Group for Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA288, 321–333 (2002).
   PubMed Web of Science ®Google Scholar
• Francis CW , ConnaghanDG, ScottWLet al. Increased plasma concentration of cross-linked fibrin polymers in acute myocardial infarction. Circulation75, 1170–1177 (1987).
   PubMed Web of Science ®Google Scholar

▪ Website

• CDC. State-specific mortality from sudden cardiac death – USA , 1999. www.cdc.gov/mmwr/preview/mmwrhtml/mm5106a3.htm
   Google Scholar